*7.3. Recommendations*

Genetic testing is becoming accessible and a ffordable in clinical practice in many countries and may be used to inform PD candidates for their suitability for DBS. Evidence is still weak to opt for either endorsing DBS or not for a certain patient only relying on the genetic background, but in the future it is probable that certain genotypes will be considered not suitable for DBS on the basis of their improbability to benefit from the e ffects. To date, genetic testing of patients undergoing DBS might be proposed in those manifesting specific phenotype features (e.g., rapid development of disability, susceptibility to behavioral complications and hallucinations) consistent with particular gene variants, such as severe *GBA* mutations, which may determine possible issues presented in the post-operative follow-up (Figure 1).

**Figure 1.** Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD) and recommendations on challenging areas related to the deep brain stimulation (DBS) selection.
